Page last updated: 2024-12-07

s 9788

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S 9788: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	107903
CHEMBL ID	85156
SCHEMBL ID	1527824
MeSH ID	M0206997

Synonyms (15)

Synonym
CHEMBL85156 ,
n,n''-diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine
bdbm50053888
n,n''-diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; h2o
s-9788
6-(4-(2,2-di(4-fluorophenyl)ethylamino)-1-piperidinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine
1,3,5-triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-n,n'-di-2-propenyl-
s9788 ,
s 9788
6-[4-[2,2-bis(4-fluorophenyl)ethylamino]piperidin-1-yl]-2-n,4-n-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
140945-01-3
SCHEMBL1527824
DTXSID80161502
GERNFWKTMKWULM-UHFFFAOYSA-N
n2,n4-diallyl-6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)piperidin-1-yl)-1,3,5-triazine-2,4-diamine

Research Excerpts

Overview

S 9788 is a novel triazinoaminopiperidine derivative which does not belong to any of the classes of compounds known to reverse multidrug resistance (MDR)

Excerpt	Reference	Relevance
"S 9788 is a novel triazinoaminopiperidine derivative which does not belong to any of the classes of compounds known to reverse multidrug resistance (MDR). "	( In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Atassi, G; Berlion, M; Bizzari, JP; Dhainaut, A; Dunn, TA; Kraus-Berthier, L; Léonce, S; Pierré, A; Régnier, G; Saint-Dizier, D, 1992)	1.73

Pharmacokinetics

Excerpt	Reference	Relevance
" Pharmacokinetic studies were performed in 24 patients."	( Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Ardiet, C; Barbet, N; Bastian, G; Catimel, G; Clavel, M; Dumortier, A; Evene, E; Foy, M; Froudarakis, M; Grossin, F; Guastalla, JP; Lucas, C; Mazier, B; Négrier, S; Rebattu, P; Sarkany, M; Tranchand, B, 1998)	0.3
" The pharmacokinetic parameters of doxorubicin in this study were close to those usually described and were not influenced by escalation of the S9788 dose."	( Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Ardiet, C; Barbet, N; Bastian, G; Catimel, G; Clavel, M; Dumortier, A; Evene, E; Foy, M; Froudarakis, M; Grossin, F; Guastalla, JP; Lucas, C; Mazier, B; Négrier, S; Rebattu, P; Sarkany, M; Tranchand, B, 1998)	0.3

Compound-Compound Interactions

Excerpt	Reference	Relevance
" We conclude that S9788 administered at the doses and schedule used in this study results in relevant plasma concentrations in humans and can safely be administered in combination with doxorubicin."	( Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Backx, A; Bleiberg, H; De Mulder, PH; Gerard, B; Hecquet, B; Lucas, C; Punt, CJ; Tueni, E; Van Oosterom, AT; Voest, EE, 1997)	0.3
"The objectives of this phase I study were to evaluate the toxic effects and the maximum tolerated dose (MTD) of S9788, a new modifier of multidrug resistance (MDR), when given alone and in combination with doxorubicin to patients with advanced solid tumors; to achieve a potentially active plasma concentration of S9788; and to study the pharmacokinetics of both drugs."	( Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Ardiet, C; Barbet, N; Bastian, G; Catimel, G; Clavel, M; Dumortier, A; Evene, E; Foy, M; Froudarakis, M; Grossin, F; Guastalla, JP; Lucas, C; Mazier, B; Négrier, S; Rebattu, P; Sarkany, M; Tranchand, B, 1998)	0.3
" S9788 was given alone as a 30-min infusion at day 1 and in combination with a 50-mg/m2 bolus of doxorubicin at days 8 and 29."	( Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Ardiet, C; Barbet, N; Bastian, G; Catimel, G; Clavel, M; Dumortier, A; Evene, E; Foy, M; Froudarakis, M; Grossin, F; Guastalla, JP; Lucas, C; Mazier, B; Négrier, S; Rebattu, P; Sarkany, M; Tranchand, B, 1998)	0.3

Dosage Studied

Excerpt	Relevance	Reference
" In this situation, the selection of a correct assay dosage to study the MDR modulation mechanism was a problem."	( Simultaneous determination of cytotoxic (adriamycin, vincristine) and modulator of resistance (verapamil, S 9788) drugs in human cells by high-performance liquid chromatography and ultraviolet detection. Atassi, G; Dubois, J; Hanocq, M; Tassin, JP, 1997)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID154221	Percent of cell viability of P388/VCR-20 murine leukemia cells remaining after inoculation with the modulator alone	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID53604	Increase in adriamycin uptake in modulator-treated cells relative to untreated cells at a concentration of 10 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID94166	Increase in adriamycin uptake in modulator-treated cells relative to untreated KB-A1 cells at a concentration of 5 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID121701	Ratio of survival time of mice treated with VCR (0.25 mg/kg ip)+modulator given at the optimal dose of 200 mg/kg po/survival time of mice treated with VCR alone.	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID153489	Antitumor activity of vincristine against P388 leukemia cell line in mice at a dose of 100 mg/kg.	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID681334	TP_TRANSPORTER: transepithelial transport in Caco 2 cell	2004	Pharmaceutical research, May, Volume: 21, Issue:5	Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
AID680486	TP_TRANSPORTER: inhibition of JC-1 uptake (JC-1: ca 0.1 uM, S9788: 5 uM) in K562 and K562/ADR cells, flow cytometry	1997	Leukemia, Jul, Volume: 11, Issue:7	Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe.
AID53608	In vitro activity in DC-3F/AD cell line Ratio of IC50(adriamycin alone) / IC50(adriamycin + modulator) at a concentration of 10 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID154130	Antitumor activity of vincristine against P388/VCR leukemia in mice at a dose of 50 mg/kg	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID154128	Antitumor activity of vincristine against P388/VCR leukemia in mice at a dose of 100 mg/kg	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID53605	Increase in adriamycin uptake in modulator-treated cells relative to untreated cells at a concentration of 5 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID53606	Compound was evaluated for in vitro activity in DC-3F/AD cell line (Ratio of IC50(adriamycin alone) / IC50(adriamycin + modulator) at a concentration of 5 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID153490	Antitumor activity of vincristine against P388 leukemia cell line in mice at a dose of 50 mg/kg	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID95582	Inhibition of [3H]D-888 binding to L-type [Ca2+] channel of membranes from rat skeletal muscle	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID94173	Percent of cell viability remaining after incubating the cells with the modulator alone	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID150364	MDR-reversal property tested in vitro on P388/VCR-20 cells, resistance was induced by vincristine	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID94163	MDR-reversal property tested in vitro on KB-A1 cells, resistance was induced by adriamycin	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID53616	Percent of cell viability remaining after incubating with a 10 uM concentration	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID53614	Percent of cell viability remaining after incubating the cells with the modulator alone a concentration of 5 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID94169	In vitro activity in KB-A1 cell line activity expressed as fold reversion (Ratio of IC50(adriamycin alone) / IC50(adriamycin + modulator) at a concentration of 5 uM	1992	Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13	New triazine derivatives as potent modulators of multidrug resistance.
AID94168	Percent of cell viability of KB-A1 human epidermoid carcinoma remaining after inoculation with the modulator alone	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	40 (90.91)	18.2507
2000's	4 (9.09)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.16 (24.57)
Research Supply Index	3.99 (2.92)
Research Growth Index	4.15 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.16)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (8.16%)	5.53%
Reviews	3 (6.12%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	12.07	26	1	aromatic ether; nitrile; polyether; tertiary amino compound
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	1.99	1	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.49	8	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.39	2	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.02	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.02	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.03	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
talinolol [no description available]	2.02	1	0	ureas
iodomycin iodomycin: structure given in first source	1.99	1	0
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.67	3	0
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.41	2	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.02	1	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
daunorubicinol daunorubicinol: main metabolite of daunomycin. (13S)-13-dihydrodaunorubicin : The (13S)-diastereomer of 13-dihydrodaunorubicin.	1.99	1	0	13-dihydrodaunorubicin
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.02	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
azidopine azidopine: structure given in first source	2.39	2	0	benzamides
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	1.98	1	0	diarylmethane
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.43	2	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
hydroxypropyl-gamma-cyclodextrin [no description available]	2.02	1	0
quinine [no description available]	4	4	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	1.99	1	0	organic cation; xanthene dye	fluorochrome
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	4.35	6	0	homodetic cyclic peptide
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.39	2	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	1.98	1	0	diarylmethane
pirarubicin [no description available]	3.78	3	0	anthracycline
technetium tc 99m sestamibi Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.	2.4	2	0
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	1.98	1	0
piperidines Piperidines: A family of hexahydropyridines.	9.54	41	4
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	3.69	10	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.02	1	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies	Trials
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	3.08	5	0
Experimental Leukemia [description not available]	1.99	1	0
Adenocarcinoma, Basal Cell [description not available]	2.9	4	0
Breast Cancer [description not available]	3.08	5	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.9	4	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.08	5	0
Di Guglielmo Disease [description not available]	1.98	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	1.98	1	0
Leucocythaemia [description not available]	2.39	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.39	2	0
Cancer of the Thyroid [description not available]	2.39	2	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.39	2	0
Carcinoma, Medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)	1.98	1	0
Benign Neoplasms [description not available]	4.85	4	2
Leukemia, Lymphocytic, T Cell [description not available]	3.77	2	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.85	4	2
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	3.77	2	1
Experimental Neoplasms [description not available]	1.98	1	0
Anaplastic Astrocytoma [description not available]	1.98	1	0
Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)	1.98	1	0
Kahler Disease [description not available]	2.9	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.9	1	0
Cancer of Kidney [description not available]	4.7	2	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	4.7	2	1
Carcinoma, Anaplastic [description not available]	1.99	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.68	3	0
Adenocarcinoma Of Kidney [description not available]	3.38	1	1
Colorectal Cancer [description not available]	3.38	1	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	3.38	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.38	1	1
Bradyarrhythmia [description not available]	3.38	1	1
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	3.38	1	1
Arrhythmia [description not available]	3.38	1	1
Torsade de Pointes [description not available]	3.38	1	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	3.38	1	1
Carcinoma, Epidermoid [description not available]	1.98	1	0
Cancer of Colon [description not available]	1.98	1	0
Acute Myelogenous Leukemia [description not available]	1.98	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.98	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	1.98	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.98	1	0

chemdatabank.com